What is new about ovarian malignancies?

Kinga Grabska; Izabela Pilarska; Marta Magdalena Fudalej; Andrzej Deptała; Anna Badowska-Kozakiewicz

doi:10.5114/wo.2021.112037

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2021
vol. 25

Send email

Copy url:

abstract:

Review paper

What is new about ovarian malignancies?

Kinga Grabska

¹

,

Izabela Pilarska

¹

,

Marta Magdalena Fudalej

²

,

Andrzej Deptała

²

,

Anna Badowska-Kozakiewicz

²

Students’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland

Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland

Contemp Oncol (Pozn) 2021; 25 (4): 225–231

DOI: https://doi.org/10.5114/wo.2021.112037

Online publish date: 2021/12/29

View full text Get citation

PlumX metrics:

Ovarian cancer is one of the most prevalent pathologies in gynaecology. This malignancy can be divided into 2 large groups: epithelial and non-epithelial. Because epithelial ovarian cancers (EOC) are the most commonly diagnosed, this paper focuses on the latest therapies associated with this disease. Due to the difficult diagnosis, EOC is frequently detected in the advanced stage. The treatment is usually complex and requires specialist knowledge. Advances and new ideas, such as identification of various genes and molecules that can serve as prognostic factors, might increase patients’ chances of survival; they may contribute to optimization of patients’ treatment, deciding whether to use aggressive treatment strategies, and predicting chemoresistance. Moreover, new strategies might also improve the quality of life of patients. The study aimed to analyse and discuss the latest reports on new methods of managing EOC.

keywords:

What is new about ovarian malignancies?

Kinga Grabska 1 , Izabela Pilarska 1 , Marta Magdalena Fudalej 2 , Andrzej Deptała 2 , Anna Badowska-Kozakiewicz 2

ovarian cancer, immunotherapy, chemotherapy, epithelial cancer, treatment

Kinga Grabska

¹

,

Izabela Pilarska

¹

,

Marta Magdalena Fudalej

²

,

Andrzej Deptała

²

,

Anna Badowska-Kozakiewicz

²